Recent Updates — SLBT

SL Science Holding Limited reported unaudited net revenue of $1,386,608 for the six months ended June 30, 2026, a 22.8% increase from the prior year period, driven by its shift to a B2B wholesale distribution model in Taiwan. The company posted a gross profit margin of 40.2% and a net loss of $2,162,205, reflecting increased research and development expenses for its CD-19 Armed-T and GDT cell therapy platforms. Concurrently, the company completed its reverse recapitalization with Horizon Space Acquisition II Corp on June 12, 2026, listing on Nasdaq under the ticker SLBT and raising $7.8 million through a PIPE financing transaction.

On August 24, 2026, Mr. Johnson Lau resigned as Vice President of Finance at SL Science Holding Limited, with the resignation effective August 31, 2026. The Board accepted the resignation, which was not due to any disagreement regarding operations or policies. SL Science Holding Limited operates in the scientific and laboratory services industry.